{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:05:50Z","timestamp":1740128750009,"version":"3.37.3"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Rotary International","award":["PP14BMF0003"],"award-info":[{"award-number":["PP14BMF0003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We conducted a trial in Nigeria to assess the immunogenicity of the new bivalent oral poliovirus vaccine + inactivated poliovirus vaccine (bOPV+IPV) immunization schedule and gains in type 2 immunity with addition of second dose of IPV. The trial was conducted in August 2016\u2013March 2017, well past the trivalent OPV-bOPV switch in April 2016.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an open-label, 2-arm, noninferiority, multicenter, randomized, controlled trial. We enrolled 572 infants aged \u226414 days and randomized them into 2 arms. Arm A received bOPV at birth, 6, and 10 weeks, bOPV+IPV at week 14, and IPV at week 18. Arm B received IPV each at 6, 10, and 14 weeks and bOPV at 18 weeks of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seroconversion rates for poliovirus types 1 and 3, respectively, were 98.9% (95% confidence interval [CI], 96.7\u201399.8) and 98.1% (95% CI, 88.2\u201394.8) in Arm A and 89.6% (95% CI, 85.4\u201393.0) and 98.5% (95% CI, 96.3\u201399.6) in Arm B. Type 2 seroconversion with 1 dose IPV in Arm A was 72.0% (95% CI, 66.2\u201377.3), which increased significantly with addition of second dose to 95.9% (95% CI, 92.8\u201397.9).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This first trial on the new Expanded Program on Immunization (EPI) schedule in a sub-Saharan African country demonstrated excellent immunogenicity against poliovirus types 1 and 3 and substantial\/enhanced immunogenicity against poliovirus type 2 after 1 to 2 doses of IPV, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa726","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T04:15:06Z","timestamp":1605586506000},"page":"299-307","source":"Crossref","is-referenced-by-count":2,"title":["Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children"],"prefix":"10.1093","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-2691","authenticated-orcid":false,"given":"Beckie N","family":"Tagbo","sequence":"first","affiliation":[{"name":"Institute of Child Health\/Department of Paediatrics, University of Nigeria Teaching Hospital , Enugu , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Verma","sequence":"additional","affiliation":[{"name":"World Health Organization , Ave Appia, Geneva , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zubairu M","family":"Mahmud","sequence":"additional","affiliation":[{"name":"National Primary Health Care Development Agency , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kolade","family":"Ernest","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, University of Ilorin Teaching Hospital , Ilorin , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roosevelt O","family":"Nnani","sequence":"additional","affiliation":[{"name":"Institute of Child Health, University of Nigeria Teaching Hospital , Enugu , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinedu","family":"Chukwubike","sequence":"additional","affiliation":[{"name":"Institute of Child Health, University of Nigeria Teaching Hospital , Enugu , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehinde T","family":"Craig","sequence":"additional","affiliation":[{"name":"World Health Organization , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullahi","family":"Hamisu","sequence":"additional","affiliation":[{"name":"World Health Organization , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C","family":"Weldon","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M","family":"Oberste","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visalakshi","family":"Jeyaseelan","sequence":"additional","affiliation":[{"name":"World Health Organization , Ave Appia, Geneva , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Braka","sequence":"additional","affiliation":[{"name":"World Health Organization , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Mkanda","sequence":"additional","affiliation":[{"name":"World Health Organization, Regional Office for Africa , Brazzaville , Democratic Republic of the Congo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"Esangbedo","sequence":"additional","affiliation":[{"name":"Pediatrics Association of Nigeria , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebiyi","family":"Olowu","sequence":"additional","affiliation":[{"name":"Pediatrics Association of Nigeria , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Nwaze","sequence":"additional","affiliation":[{"name":"National Primary Health Care Development Agency , Abuja , Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland W","family":"Sutter","sequence":"additional","affiliation":[{"name":"World Health Organization , Ave Appia, Geneva , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"volume-title":"WHA41.28 - Global eradication of poliomyelitis by the year 2000","author":"Forty-First World Health Assembly","key":"2022082412282865000_CIT0001"},{"author":"Global Eradication Initiative","key":"2022082412282865000_CIT0002"},{"author":"Global Eradication Initiative","key":"2022082412282865000_CIT0003"},{"key":"2022082412282865000_CIT0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6820a3","article-title":"Progress toward polio eradication","volume":"68","author":"Greene","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082412282865000_CIT0005"},{"author":"World Health Organization","key":"2022082412282865000_CIT0006"},{"author":"Global Eradication Initiative","key":"2022082412282865000_CIT0007"},{"key":"2022082412282865000_CIT0008","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"author":"Hampton","key":"2022082412282865000_CIT0009"},{"author":"Global Eradication Initiative","key":"2022082412282865000_CIT0010"},{"author":"World Health Organization | Regional Office for Africa","key":"2022082412282865000_CIT0011"},{"key":"2022082412282865000_CIT0012","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1093\/infdis\/175.Supplement_1.S215","article-title":"Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand","volume":"175","author":"WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines","year":"1997","journal-title":"J Infect Dis"},{"key":"2022082412282865000_CIT0013","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S1473-3099(17)30358-4","article-title":"Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study","volume":"17","author":"Taniuchi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022082412282865000_CIT0014","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"Lancet"},{"volume-title":"SAS 9.1.3 help and documentation","year":"2002\u20132004","author":"SAS Institute Inc.","key":"2022082412282865000_CIT0015"},{"key":"2022082412282865000_CIT0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"2022082412282865000_CIT0017","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/321905","article-title":"Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication","volume":"33","author":"C\u00e1ceres","year":"2001","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2022082412282865000_CIT0018","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1056\/NEJMoa054960","article-title":"Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba","volume":"356","author":"Cuba IPV Study Collaborative Group","year":"2007","journal-title":"N Engl J Med"},{"key":"2022082412282865000_CIT0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J Infect Dis"},{"author":"World Health Organization","key":"2022082412282865000_CIT0020"},{"volume-title":"Efron B and Tibshirani RJ. An Introduction to the Bootstrap","year":"1994","key":"2022082412282865000_CIT0021"},{"volume-title":"R: a language and environment for statistical computing","year":"2011","author":"R Development Core Team","key":"2022082412282865000_CIT0022"},{"key":"2022082412282865000_CIT0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"2022082412282865000_CIT0024","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O\u2019Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2022082412282865000_CIT0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/jix577","article-title":"Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan","volume":"217","author":"Saleem","year":"2018","journal-title":"J Infect Dis"},{"key":"2022082412282865000_CIT0026","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J Infect Dis"},{"key":"2022082412282865000_CIT0027","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa0800390","article-title":"Monovalent type 1 oral poliovirus vaccine in newborns","volume":"359","author":"El-Sayed","year":"2008","journal-title":"N Engl J Med"},{"key":"2022082412282865000_CIT0028","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/427810","article-title":"Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion","volume":"191","author":"Abbink","year":"2005","journal-title":"J Infect Dis"},{"key":"2022082412282865000_CIT0029","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/ciy633","article-title":"Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review","volume":"67","author":"Bandyopadhyay","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2022082412282865000_CIT0030","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/cid\/ciy649","article-title":"Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the polio eradication endgame","volume":"67","author":"Gaensbauer","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2022082412282865000_CIT0031","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0264-410X(02)00523-6","article-title":"Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules","volume":"21","author":"Ch\u00e2telet du","year":"2003","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa726\/35901433\/jiaa726.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/2\/299\/45507748\/jiaa726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/2\/299\/45507748\/jiaa726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T12:58:41Z","timestamp":1661345921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/2\/299\/5999481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,24]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa726","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2022,7,15]]},"published":{"date-parts":[[2020,11,24]]}}}